Advertisement
Advertisement
RGEN
Repligen Corp
125.03
USDSponsored
-0.84
-0.66%
Mar 05, 16:00 UTC -5
Closed
Pre-Market
124.34
-0.69
-0.55%
RGEN Earnings Reports
Positive Surprise Ratio
RGEN beat 34 of 41 last estimates.
83%
Next Report
Date of Next Report
Apr 27, 2026
Estimate for Q1 26 (Revenue/ EPS)
$195.75M
/$0.38
Implied change from Q4 25 (Revenue/ EPS)
-1.09%
/-22.45%
Implied change from Q1 25 (Revenue/ EPS)
+15.71%
/-2.56%
Repligen Corp earnings per share and revenue
On Feb 24, 2026, RGEN reported earnings of 0.49 USD per share (EPS) for Q4 25, beating the estimate of 0.44 USD, resulting in a 9.25% surprise. Revenue reached 197.91 million, compared to an expected 196.77 million, with a 0.58% difference. The market reacted with a -0.54% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 19 analysts forecast an EPS of 0.38 USD, with revenue projected to reach 195.75 million USD, implying an decrease of -22.45% EPS, and decrease of -1.09% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Liquidia Corporation Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.18
Actual
$0.15
Surprise
-18.48%
Kura Oncology, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.62
Actual
-$0.92
Surprise
-47.84%
CorMedix Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.83
Actual
$0.61
Surprise
-26.73%
Keros Therapeutics, Inc. Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
-$0.64
Actual
-$0.86
Surprise
-34.10%
REGENXBIO Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.97
Actual
-$1.30
Surprise
-33.31%
Lexicon Pharmaceuticals, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.07
Actual
-$0.04
Surprise
+43.18%
Contineum Therapeutics, Inc. Class A Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.41
Actual
-$0.49
Surprise
-18.41%
Lineage Cell Therapeutics, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.05
Actual
$0.00
Surprise
+100.00%
Atea Pharmaceuticals, Inc. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.54
Actual
-$0.56
Surprise
-5.44%
Aligos Therapeutics, Inc. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$1.88
Actual
-$1.91
Surprise
-1.11%
FAQ
What were Repligen Corp's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Repligen Corp reported EPS of $0.49, beating estimates by 9.25%, and revenue of $197.91M, 0.58% above expectations.
How did the market react to Repligen Corp's Q4 2025 earnings?
The stock price moved down -0.54%, changed from $135.40 before the earnings release to $134.67 the day after.
When is Repligen Corp expected to report next?
The next earning report is scheduled for Apr 27, 2026.
What are the forecasts for Repligen Corp's next earnings report?
Based on 19
analysts, Repligen Corp is expected to report EPS of $0.38 and revenue of $195.75M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement